Results 181 to 190 of about 201,026 (256)

Serious Infection in Crohn's Disease Patients Treated With Ustekinumab: US Food and Drug Administration Active Postmarket Risk Identification and Analysis in the Sentinel Initiative

Clinical Pharmacology &Therapeutics, EarlyView.
The U.S. Food and Drug Administration (FDA) used an Active Postmarket Risk Identification and Analysis (ARIA) system to address a safety issue (serious infection) identified during clinical review of an application to market ustekinumab as a treatment for Crohn's disease (CD). FDA used an active‐comparator new‐user cohort design, data from six Sentinel
Joel L. Weissfeld, Geetha S. Iyer, Suna C. Seo, Andrew Giffin, Andrew L. Simon, Sheryl A. Kluberg, Emma R. Hoffman, Jamal T. Jones, Sarah K. Dutcher, Joyce A. Korvick   +9 more
wiley   +1 more source

Concomitant 5‐Aminosalicylic Acid Does Not Affect the Efficacy of Janus Kinase Inhibitors in Ulcerative Colitis

Clinical Pharmacology &Therapeutics, EarlyView.
We evaluated whether concomitant 5‐aminosalicylic acid (5‐ASA) influences clinical remission in patients with ulcerative colitis (UC) receiving Janus kinase inhibitors (JAKi). In this retrospective, multicenter cohort study, UC patients receiving tofacitinib (n = 181), upadacitinib (n = 313), or filgotinib (n = 139) were included.
Antonio Tursi, Andrea Pasta, Walter Elisei, Brigida Barberio, Giammarco Mocci, Giovanni Maconi, Antonietta Gerarda Gravina, Raffaele Pellegrino, Giorgia Bodini, Edoardo Vincenzo Savarino, Alfredo Papa, Italian Network for Inflammatory Bowel Diseases (IN‐IBD), Davide G. Ribaldone, Antonio Ferronato, Greta Lorenzon, Davide Checchin, Francesca Lambroglia, Francesco Ferrara, Carla Felice, Giovanni Cataletti, Giorgia Bodini, Andrea Pasta, Giovanni Aragona, Patrizia Perazzo, Federica Gaiani, Stefano Kayali, Fabio Cortellini, Francesco Costa, Lorenzo Bertani, Antonella Scarcelli, Mariaelena Serio, Emanuele Bendia, Laura Bolognini, Daniele Balducci, Claudia Quatraccioni, Francesco Martini, Michele Montori, Simona Piergallini, Francesca Maria Onidi, Paolo Usai Satta, Giorgia Orrù, Raffaele Colucci, Francesco Bachetti, Gabrio Bassotti, Elisabetta Antonelli, Costantino Zampaletta, Giulia Rocco, Carlotta Sacchi, Franco Scaldaferri, Daniele Napolitano, Roberto Faggiani, Michela Di Fonzo, Rita Monterubbianesi, Cristiano Pagnini, Maria Giovanna Graziani, Maria Carla Di Paolo, Roberta Pica, Maddalena Zippi, Andrea Cocco, Claudio Cassieri, Roberto Lorenzetti, Gian Marco Giorgetti, Valeria Clemente, Patrizio Scarozza, Girolamo Bevevino, Giulia Zerboni, Federico Iacopini, Giacomo Forti, Laurino Grossi, Serafina Fiorella, Giovanni Lombardi, Marta Patturelli, Giuliana Vespere, Silvia Sedda, Vittorio D’Onofrio, Leonardo De Luca, Caterina Mucherino, Elvira D’Antonio, Laura Montesano, Pietro Capone, Guido Daniele Villani, Antonio Cuomo, Laura Donnarumma, Nicola Della Valle, Giuseppe Pranzo, Paolo Tonti, Viviana Neve, Libera Fanigliulo, Leonardo Allegretta, Alessia Immacolata Cazzato, Stefano Scorza, Manuela Marzo, Ileana Luppino, Francesco Luzza, Rocco Spagnuolo, Stefano Rodinò, Ladislava Sebkova, Antonio De Medici, Domenico Catarella, Dario D’Agostino, Elisabetta Di Bartolo   +100 more
wiley   +1 more source

The effects of sodium–glucose cotransporter 2 inhibitors on the ‘forgotten’ right ventricle

ESC Heart Failure, Volume 12, Issue 2, Page 1045-1058, April 2025.
Abstract With the progress in diagnosis, treatment and imaging techniques, there is a growing recognition that impaired right ventricular (RV) function profoundly affects the prognosis of patients with heart failure (HF), irrespective of their left ventricular ejection fraction (LVEF).
Liangzhen Qu, Xueting Duan, Han Chen
wiley   +1 more source

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source

SV2A expression in blood cells as a possible biomarker candidate for levetiracetam treatment response

Epilepsia, EarlyView.
Abstract Objective This study was undertaken to evaluate whether synaptic vesicle protein 2A (SV2A) expression on peripheral immune cells predicts treatment response to levetiracetam in epilepsy. Methods High‐dimensional flow cytometry was used to prospectively assess SV2A expression on immune cells from levetiracetam responders, nonresponders, and ...
Johannes Lang, Mathias Linnerbauer, Jeanne Cuny, Veit Rothhammer, Hajo Hamer   +4 more
wiley   +1 more source

Chronic Upper Respiratory Tract Infections [PDF]

Proceedings of the Royal Society of Medicine, 1951
openaire   +2 more sources

Soticlestat as an adjunctive therapy in children and young adults with Dravet syndrome

Epilepsia, EarlyView.
Overview of the phase 3 trial evaluating soticlestat as adjunctive therapy in children and young adults with Dravet syndrome. Abstract Objective This study evaluated the efficacy, safety, and tolerability of soticlestat as adjunctive therapy in children and young adults with Dravet syndrome (DS).
Joseph Sullivan, Kette Valente, Vicente Villanueva, Adam Strzelczyk, Rima Nabbout, Eiji Nakagawa, Yuehua Zhang, Marta Zolnowska, Yasir Khan, Cheng Dong, Samuel Hsiao, Sarah I. Sheikh, Philipp von Rosenstiel, Mahnaz Asgharnejad, Venkatesha Murthy   +14 more
wiley   +1 more source

An n‐of‐1 gene‐directed drug repurposing trial for an ultrarare genetic condition

Epilepsia, EarlyView.
Abstract Objective Gain‐of‐function (GoF) variants in the KCNC1 potassium channel subunit gene (Kv3.1) cause motor/cognitive delays and hypotonia and have been associated with seizures. Fluoxetine has inhibitory effects on Kv3.1. However, open‐label nonrandomized administration is insufficient to guide clinical decision‐making in ultrarare conditions ...
Vedika Jha, Christina Tsetsos, Mark Bedford, Gregory Costain, Sunita Vohra, Juan Pablo Diaz Martinez, Elise Heon, Jacob Vorstman, Carolina Gorodetsky, Ajoy Vincent, Jesiqua Rapley, Lori Anderson, Evdokia Anagnostou, Danielle A. Baribeau   +13 more
wiley   +1 more source

Intestinal microbiome alterations in pediatric epilepsy: Implications for seizures and therapeutic approaches

Epilepsia Open, EarlyView.
Abstract The intestinal microbiome plays a pivotal role in maintaining host health through its involvement in gastrointestinal, immune, and central nervous system (CNS) functions. Recent evidence underscores the bidirectional communication between the microbiota, the gut, and the brain and the impact of this axis on neurological diseases, including ...
Teresa Ravizza, Greta Volpedo, Antonella Riva, Pasquale Striano, Annamaria Vezzani   +4 more
wiley   +1 more source

Ketogenic diet for infantile epileptic spasms

Epilepsia Open, EarlyView.
Abstract Approximately half of all cases of Infantile Epileptic Spasms Syndrome (IESS) do not respond to vigabatrin and hormonal therapies. There is no clear consensus as to the second‐line therapy for IESS. Ketogenic diet (KD) has emerged as an effective treatment for certain drug‐resistant epilepsies and in many cases of IESS.
Morris H. Scantlebury, Anamika Choudhary, Andy Cheuk‐Him Ng, Cezar Gavrilovici   +3 more
wiley   +1 more source